Abstract
Lymphomas are subdivided in Hodgkin’s disease (HD) and non-Hodgkin’s lymphomas (NHL). Essentially the medications used are of two types: monoclonal antibodies and chemotherapy. The side effects of treatment are grouped accordingly. The most commonly used treatment protocol in NHL is a combination of a monoclonal antibody with polychemotherapy. Hence, this chapter is subdivided according to these two treatment modalities.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Smith MR. Antibodies and hematologic malignancies. Cancer J. 2008;14(3):184–90.
Armitage JO. How I treat patients with diffuse large B-cell lymphoma. Blood. 2007;110(1):29–36.
Cheson BD, Leonard JP. Monoclonal antibody therapy for B-cell non-Hodgkin’s lymphoma. N Engl J Med. 2008;359:613–26.
Friedberg JW, Vose JM, Kelly JL, Young F, Bernstein SH, Peterson D, et al. The combination of bendamustine, bortezomib, and rituximab for patients with relapsed/refractory indolent and mantle cell non-Hodgkin lymphoma. Blood. 2011;117:2807–12. https://doi.org/10.1182/blood-2010-11-314708.
Rummel MJ, Niederle N, Maschmeyer G, Banat AG, von Gruenhagen U, Losem C, et al. Bendamustine plus rituximab (B-R) versus CHOP plus rituximab (CHOP-R) as first-line treatment in patients with indolent and mantle cell lymphomas (MCL): updated results from the StiL NHL1 study. J Clin Oncol. 2012;30:3.
Goede V, Fischer K, Humphrey K, Asikanius E, et al. Obinutuzumab (GA101) + chlorambucil or rituximab + Clb versus Clb alone in patients with CLL and co-existing medical conditions: final stage I results of the CLL11 phase 3 trial. N Engl J Med. 2014;370:1101–10.
Wierda WG, Kipps TJ, Dürig J, et al. Chemoimmunotherapy with OFC in previously untreated patients with chronic lymphocytic leukemia. Blood. 2011;117(24):6450–8.
Younes A, Gopal AK, Smith SE, et al. Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin’s lymphoma. J Clin Oncol. 2012;30(18):2183–9.
Larocca A, Cavallo F, Bringhen S, et al. Aspirin or enoxaparin thromboprophylaxis for patients with newly diagnosed multiple myeloma treated with lenalidomide. Blood. 2012;119(4):939–9.
Oehrlein K, Langer C, Sturm I, et al. Successful treatment of patients with multiple myeloma and impaired renal function with lenalidomide: results of 4 German centers. Clin Lymphoma Myelome Leuk. 2012;12(3):191–6.
Savage KJ, Skinnider B, Al-Mansour M, Sehn LH, Gascoyne RD, Connors JM. Treating limited-stage nodular lymphocyte predominant Hodgkin lymphoma similarly to classical Hodgkin lymphoma with ABVD may improve outcome. Blood. 2011;118:4585–90. https://doi.org/10.1182/blood-2011-07-365932.
Zinzani PL. Clinical experience with fludarabine in indolent non-Hodgkin’s lymphoma. Hematol J. 2004;5(Suppl 1):S38–49.
Economopoulos T, Psyrri A, Fountzilas G, Tsatalas C, Anagnostopoulos A, Papageorgiou S, et al. Phase II study of low-grade non-Hodgkin lymphomas with fludarabine and mitoxantrone followed by rituximab consolidation: promising results in marginal zone lymphoma. Leuk Lymphoma. 2008;49(1):68–74.
Johnson SA. Use of fludarabine in the treatment of mantle cell lymphoma, Waldenström’s macroglobulinemia and other uncommon B- and T-cell lymphoid malignancies. Hematol J. 2004;5(Suppl 1):S50–61.
Weidmann E, Kim SZ, Rost A, Schuppert H, Seipelt G, Hoelzer D, Mitrou PS. Bendamustine is effective in relapsed or refractory aggressive non-Hodgkin’s lymphoma. Ann Oncol. 2012;13(8):1285–9.
Ohmachi K, Ando K, Ogura M, Uchida T, Itoh K, Kubota N, Japanese Bendamustine Lymphoma Study Group, et al. Multicenter phase II study of bendamustine for relapsed or refractory indolent B-cell non-Hodgkin lymphoma and mantle cell lymphoma. Cancer Sci. 2010;101(9):2059–64.
Moreau P, Pylypenko H, Grosicki S, et al. Subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma: a randomised, phase 3, non-inferiority study. Lancet Oncol. 2011;12(5):431–40.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2018 Springer International Publishing AG, part of Springer Nature
About this chapter
Cite this chapter
Cherrier-De Wilde, S. (2018). Lymphoma. In: Dicato, M., Van Cutsem, E. (eds) Side Effects of Medical Cancer Therapy. Springer, Cham. https://doi.org/10.1007/978-3-319-70253-7_9
Download citation
DOI: https://doi.org/10.1007/978-3-319-70253-7_9
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-319-70252-0
Online ISBN: 978-3-319-70253-7
eBook Packages: MedicineMedicine (R0)